Fed. Circ. Questions If Safer OxyContin Profits Came From IP
By Dani Kass · October 7, 2024, 9:39 PM EDT
An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login